Atria Investments LLC boosted its position in Grifols, S.A. (NASDAQ:GRFS) by 11.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,095 shares of the biotechnology company’s stock after buying an additional 1,393 shares during the period. Atria Investments LLC’s holdings in Grifols, were worth $277,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Harding Loevner LP boosted its stake in shares of Grifols, by 0.3% in the first quarter. Harding Loevner LP now owns 15,294,851 shares of the biotechnology company’s stock worth $288,690,000 after buying an additional 52,316 shares during the last quarter. AKO Capital LLP acquired a new stake in Grifols, during the first quarter valued at $36,979,000. FMR LLC boosted its stake in Grifols, by 52.6% in the first quarter. FMR LLC now owns 6,352,581 shares of the biotechnology company’s stock valued at $119,905,000 after buying an additional 2,189,431 shares in the last quarter. FIL Ltd boosted its stake in Grifols, by 0.4% in the first quarter. FIL Ltd now owns 3,689,737 shares of the biotechnology company’s stock valued at $69,644,000 after buying an additional 15,142 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Grifols, by 25.1% in the first quarter. JPMorgan Chase & Co. now owns 1,926,442 shares of the biotechnology company’s stock valued at $36,362,000 after buying an additional 385,998 shares in the last quarter. Hedge funds and other institutional investors own 22.69% of the company’s stock.
Grifols, S.A. (NASDAQ:GRFS) traded up 0.69% on Friday, reaching $20.55. The company’s stock had a trading volume of 222,396 shares. The company has a market cap of $28.08 billion, a P/E ratio of 42.55 and a beta of 0.97. The company has a 50-day moving average price of $20.88 and a 200 day moving average price of $19.69. Grifols, S.A. has a 12 month low of $14.27 and a 12 month high of $22.83.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/11/grifols-s-a-nasdaqgrfs-shares-bought-by-atria-investments-llc-updated-updated-updated.html.
Several equities research analysts have recently weighed in on GRFS shares. Zacks Investment Research raised Grifols, from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday, July 4th. Bank of America Corporation reissued a “buy” rating on shares of Grifols, in a research report on Tuesday, July 4th. BidaskClub raised Grifols, from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Goldman Sachs Group, Inc. (The) cut Grifols, from a “buy” rating to a “neutral” rating in a research report on Friday, June 30th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $24.00.
What are top analysts saying about Grifols S.A.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Grifols S.A. and related companies.